Related Experiment Video
Updated: Aug 10, 2026

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure
Published on: March 20, 2012
[Estimation of the teratogenic effects of therapeutic drugs]
Abstract:
Therapeutics may induce embryological abnormalities in the laboratory animal, Now, it is known from experience that the currently applied experimental procedures allow to detect potential teratogenic risks in animals. There is only a slight possibility that a new therapeutic would be highly teratogenic as very special conditions are fundamental for the exteriorisation of the teratogenic effect, such as the sensibility and the developmental stage of the embryo, its genetic constitution and the physiology and pathology of the mother. The wellknown difficulties associated with the extrapolation of experimental results require that more species are used and that historical control data for each species and strains are kept allowing a global assessment of the results which better weighs the potential risk against the therapeutic activity of each new therapeutic.
Insights
Experimental procedures can detect teratogenic risks in animals. However, highly teratogenic effects are rare, requiring specific conditions for manifestation, necessitating careful risk-benefit analysis for new therapeutics.
Area of Science:
- Pharmacology and Toxicology
- Developmental Biology
- Risk Assessment
Context:
- Current experimental models are established for detecting potential teratogenic risks of therapeutics in laboratory animals.
- The manifestation of teratogenic effects is contingent upon specific conditions, including embryonic stage, genetic factors, and maternal physiology.
- Extrapolation of animal study findings to human subjects presents challenges.
Purpose:
- To evaluate the efficacy of existing experimental procedures in identifying teratogenic risks associated with new therapeutics.
- To highlight the complex interplay of factors influencing teratogenicity.
- To emphasize the need for robust data interpretation in drug development.
Summary:
- Experimental models effectively identify potential teratogenic risks in animals.
- Highly teratogenic outcomes are improbable, requiring precise conditions like embryonic sensitivity, maternal health, and genetic makeup.
- Challenges in extrapolating animal data necessitate the use of multiple species and historical control data for comprehensive risk-benefit assessment.
Impact:
- Informs regulatory agencies and pharmaceutical developers on the interpretation of preclinical safety data.
- Contributes to the development of safer therapeutics by refining risk assessment strategies.
- Enhances the understanding of factors influencing developmental toxicity, aiding in the design of more predictive preclinical studies.
More Related Videos
17:28Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
Published on: June 17, 2015
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
Related Concept Videos
Factors Affecting Drug Response: Overview
Teratogenicity
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drug Toxicity: Risk factors
Drug Toxicity: Dose-Dependent Reactions
Toxicity Testing in Animals